Cargando…

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

BACKGROUND AND OBJECTIVE: This study aimed to develop and evaluate a population pharmacokinetic model and limited sampling strategy for isoniazid to be used in model-based therapeutic drug monitoring. METHODS: A population pharmacokinetic model was developed based on isoniazid and acetyl-isoniazid p...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Beek, Stijn W., ter Heine, Rob, Alffenaar, Jan-Willem C., Magis-Escurra, Cecile, Aarnoutse, Rob E., Svensson, Elin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249295/ https://www.ncbi.nlm.nih.gov/pubmed/33615419 http://dx.doi.org/10.1007/s40262-020-00971-2

Ejemplares similares

Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
por: Seijger, Charlotte, et al.
Publicado: (2019)

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis
por: Saktiawati, Antonia Morita I., et al.
Publicado: (2019)

Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
por: Ruslami, Rovina, et al.
Publicado: (2022)

Model‐Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities
por: Keizer, Ron J., et al.
Publicado: (2018)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial
por: Espinosa-Pereiro, Juan, et al.
Publicado: (2022)

Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study
por: Ghimire, Samiksha, et al.
Publicado: (2023)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
por: Aguilar Diaz, Jessica M, et al.
Publicado: (2023)

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
por: Sturkenboom, Marieke G. G., et al.
Publicado: (2021)

Dose of Isoniazid in Renal Disease for Treatment of Tuberculosis
por: Sarma, G. R. K.
Publicado: (2022)

Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa
por: van Beek, Stijn W., et al.
Publicado: (2021)

Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients
por: ter Heine, Rob, et al.
Publicado: (2020)

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients
por: Zwart, Tom C., et al.
Publicado: (2020)

A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept
por: Hartman, Stan J. F., et al.
Publicado: (2020)

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
por: Koele, Simon E., et al.
Publicado: (2021)

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
por: Ayoun Alsoud, Rami, et al.
Publicado: (2023)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
por: Litjens, Carlijn H. C., et al.
Publicado: (2021)

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting
por: Yuen, Courtney M, et al.
Publicado: (2020)

The accuracy of an electronic nose to diagnose tuberculosis in patients referred to an expert centre
por: Coronel Teixeira, Rosarito, et al.
Publicado: (2023)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis
por: Walsh, Kathleen F, et al.
Publicado: (2022)

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
por: Pillay, Samantha, et al.
Publicado: (2022)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Perspective for Precision Medicine for Tuberculosis
por: Lange, Christoph, et al.
Publicado: (2020)

Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans
por: van Wijk, Rob C., et al.
Publicado: (2020)

The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a Mouse Model of Multidrug-Resistant Tuberculosis
por: van Soolingen, Dick, et al.
Publicado: (2010)

Adequacy of the 10 mg/kg Daily Dose of Antituberculosis Drug Isoniazid in Infants under 6 Months of Age
por: López-Ramos, Maria Goretti, et al.
Publicado: (2023)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
por: van Beek, Stijn W, et al.
Publicado: (2022)

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
por: Jacobs, Tom G, et al.
Publicado: (2020)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations
por: Wasserman, Sean, et al.
Publicado: (2020)

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
por: Rens, Neil E, et al.
Publicado: (2020)

Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis
por: Said, Bibie N, et al.
Publicado: (2021)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a7eis8v7s7imhlvve65i1hnlle